Passa al contenuto
Merck

SAR of 3,4-dihydropyrido[3,2-d]pyrimidone p38 inhibitors.

Bioorganic & medicinal chemistry letters (2003-11-01)
Luping Liu, John E Stelmach, Swaminathan R Natarajan, Meng-Hsin Chen, Suresh B Singh, Cheryl D Schwartz, Catherine E Fitzgerald, Stephen J O'Keefe, Dennis M Zaller, Dennis M Schmatz, James B Doherty
ABSTRACT

Development for a class of potent 3,4-dihydropyrido(3,2-d)pyrimidone inhibitors of p38a MAP kinase is described. Modification of N-1 aryl and C-6 arylsulfide in 3,4-dihydropyrido(3,2-d)pyrimidone analogues for the interaction with the hydrophobic pockets in p38 active site is also discussed.